{"id":"NCT02045862","sponsor":"Astellas Pharma Europe B.V.","briefTitle":"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-17","primaryCompletion":"2016-09-08","completion":"2016-09-08","firstPosted":"2014-01-27","resultsPosted":"2018-06-06","lastUpdate":"2024-10-31"},"enrollment":1829,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Bladder Overactive","Overactive Bladder","Urgency Incontinence","Urinary Bladder Diseases\\Urologic Diseases"],"interventions":[{"type":"DRUG","name":"Solifenacin succinate","otherNames":["Vesicare","Vesitrim","YM905","Vesikur"]},{"type":"DRUG","name":"Mirabegron","otherNames":["Myrbetriq","YM178","Betmiga","Betanis"]},{"type":"DRUG","name":"Placebo to match solifenacin","otherNames":[]},{"type":"DRUG","name":"Placebo to match mirabegron","otherNames":[]}],"arms":[{"label":"Mirabegron 50 mg","type":"ACTIVE_COMPARATOR"},{"label":"Solifenacin 5 mg","type":"ACTIVE_COMPARATOR"},{"label":"Solifenacin 5 mg + Mirabegron 50 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for long term use.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 56 weeks)","effectByArm":[{"arm":"Mirabegron 50 mg","deltaMin":126,"sd":null},{"arm":"Solifenacin 5 mg","deltaMin":134,"sd":null},{"arm":"Solifenacin 5 mg + Mirabegron 50 mg","deltaMin":596,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":251,"countries":["United States","Australia","Belgium","Bulgaria","Canada","Czechia","Denmark","Estonia","Finland","Germany","Hungary","Italy","Latvia","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","Norway","Poland","Romania","Russia","Singapore","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["29866467"],"seeAlso":["https://astellasclinicalstudyresults.com/study.aspx?ID=246"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":305},"commonTop":["Dry mouth","Nasopharyngitis"]}}